Lenalidomide in Multiple Myeloma

This is a clinical practice guideline for adult patients with multiple myeloma. The guideline reviews the use of lenalidomide as a treatment option for previously untreated or relapsed/refractory multiple myeloma as compared to non-lenalidomide treatments. Use of lenalidomide as a maintenance or consolidation treatment (following transplant and non-transplant treatments) is examined and strategies for managing toxicity are discussed. Outcomes of interest include disease progression, adverse events, safety, and overall survival.